

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.  
Petitioner

v.

GENENTECH, INC.  
Patent Owner

---

U.S. Patent No.6,407,213

Case IPR2017-02032

---

**EXPERT DECLARATION OF GEOFFREY HALE, PH.D.  
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF  
PATENT NO.6,407,213**

## TABLE OF CONTENTS

	<u>Page</u>
<b>I.</b> QUALIFICATIONS AND BACKGROUND.....	1
<b>A.</b> Education and Experience.....	1
<b>B.</b> Bases for Opinions and Materials Considered.....	4
<b>C.</b> Scope of Work.....	5
<b>II.</b> LEGAL STANDARDS.....	5
<b>III.</b> PERSON OF ORDINARY SKILL IN THE ART.....	9
<b>IV.</b> SUMMARY OF OPINIONS.....	11
<b>V.</b> THE '213 PATENT [EX. 1001].....	17
<b>VI.</b> BACKGROUND.....	33
<b>A.</b> Antibody Structure and Function.....	33
<b>B.</b> Monoclonal Antibodies Expanded Therapeutic and Diagnostic Uses of Antibodies.....	35
<b>C.</b> Immunogenic Reaction in Humans With Monoclonal Antibody Therapy.....	37
<b>D.</b> Molecular Characterization of Antibody Structure and Function.....	38
<b>E.</b> Antigen Binding Regions.....	42
<b>F.</b> Framework Region Important for Antigen Binding.....	47
<b>G.</b> Chimeric Antibodies.....	51
<b>H.</b> Antibody Humanization.....	53
<b>VII.</b> SCOPE AND CONTENT OF THE PRIOR ART REFERENCES.....	68
<b>A.</b> EP 0403156 “Improved Monoclonal Antibodies Against the Human Alpha/Beta T-Cell Receptor, Their Production and Use” Published December 19, 1990 (“Kurrle”) [Ex. 1071].....	68
<b>B.</b> Queen <i>et al.</i> “A Humanized Antibody that Binds to the Interleukin 2 Receptor” <i>PNAS</i> 86:10029-33 (1989) (“Queen 1989”) [Ex. 1034]....	71
<b>C.</b> PCT Publication No. WO 90/07861 (“Queen 1990”) [Ex. 1050].....	75
<b>D.</b> U.S. Patent No. 5,530,101 (“the ’101 patent”) [Ex. 1136].....	79
<b>E.</b> Jones <i>et al.</i> , “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” <i>Nature</i> 321:522-25 (1986) (“Jones”).....	81
<b>F.</b> Protein Data Bank Database.....	83
<b>G.</b> Tramontano <i>et al.</i> “Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the VH Domains of Immunoglobulins” <i>J. Mol. Biol.</i> 215:175-82 (1990) (“Tramontano”) [Ex. 1051].....	86

<b>H.</b>	Kabat <i>et al.</i> “Sequences of Proteins of Immunological Interest”, 4 <sup>th</sup> Ed., pp. iii, 41-49, 167-76 (1987) (“Kabat 1987”) [Ex. 1052].....	87
<b>I.</b>	Chothia and Lesk. “Canonical Structures for the Hypervariable Regions of Immunoglobulins” <i>J. Mol. Biol.</i> 196:901-17 (1987) (“Chothia & Lesk”) [Ex. 1062].....	88
<b>J.</b>	Riechmann et al, “Reshaping Human Antibodies For Therapy,” <i>Nature</i> , 332:323-27 (1988) (“Riechmann”) [Ex. 1069].....	88
<b>VIII.</b>	UNPATENTABILITY OF THE ’213 PATENT .....	89
<b>A.</b>	Claims 1, 2, 4, 25, 29, 62, 63, 66, 69, 71, 75, 76, 78, 80 and 81 of the ’213 Patent are Anticipated by Kurrle [Ex. 1071] .....	89
<b>1.</b>	Claim 1 of the ’213 patent is anticipated by Kurrle.....	89
<b>2.</b>	Dependent claims 2, 25 and 29 are anticipated by Kurrle.....	91
<b>3.</b>	Independent claim 63 is anticipated by Kurrle.....	93
<b>4.</b>	Independent claim 66 and dependent claims 71, 72, 75 and 76, and 78 are anticipated by Kurrle.....	94
<b>5.</b>	Claims 4, 62, and 69 are anticipated by Kurrle .....	95
<b>6.</b>	Independent claim 80 and dependent claim 81 are anticipated by Kurrle .....	97
<b>B.</b>	Claims 1, 2, 4, 29, 62, 63, 64, 80 and 81 of the ’213 Patent are Anticipated by Queen 1990.....	99
<b>1.</b>	Independent Claim 1 of the ’213 Patent is anticipated by Queen 1990 [Ex. 1050].....	99
<b>2.</b>	Dependent Claim 2 of the ’213 Patent is anticipated by Queen 1990.....	106
<b>3.</b>	Dependent Claim 4 of the ’213 Patent is anticipated by Queen 1990.....	107
<b>4.</b>	Dependent Claim 29 of the ’213 Patent is anticipated by Queen 1990.....	107
<b>5.</b>	Independent Claim 62 of the ’213 Patent is anticipated by Queen 1990 .....	108
<b>6.</b>	Independent Claim 63 of the ’213 Patent is anticipated by Queen 1990 .....	109
<b>7.</b>	Independent Claim 64 of the ’213 Patent is anticipated by Queen 1990 .....	110
<b>8.</b>	Independent Claim 80 of the ’213 Patent is anticipated by Queen 1990 .....	112
<b>9.</b>	Dependent Claim 81 of the ’213 Patent is anticipated by Queen 1990.....	114

<b>C.</b>	Claims 1, 2, 4, 25, 29, 62-64, 66-67, 69, 71-73, 75-78, and 80-81 of the '213 Patent are obvious over Queen 1990 in view of Kurrle, and Chothia & Lesk .....	115
1.	Claim 1 is obvious over Queen 1990 and Kurrle .....	117
2.	Claims 2, 25 and 29 are obvious over Queen 1990 and Kurrle .....	121
3.	Claim 4 is obvious over Queen 1990 and Kurrle .....	123
4.	Claim 62 is obvious over Queen 1990 in view of Kurrle .....	123
5.	Claim 63 is obvious over Queen 1990 in view of Kurrle .....	124
6.	Claim 64 is obvious over Queen 1990 in view of Kurrle .....	126
7.	Claim 66 is obvious over Queen 1990 in view of Kurrle .....	128
8.	Claims 67, 71, 72, 75, 76 and 78 are obvious over Queen 1990 in view of Kurrle .....	129
9.	Claim 69 is obvious over Queen 1990 in view of Kurrle .....	131
10.	Claims 73 and 77 are obvious in view of Queen 1990, Kurrle and Chothia & Lesk .....	131
11.	Claims 80 and 81 are obvious over Queen 1990 in view of Kurrle .....	134
<b>D.</b>	Claims 1, 2, 4, 25, 29, 62, 63, 64, 66, 69, 71, 73, 75-78, 80 and 81 are Anticipated by Jones [Ex. 1033] .....	136
1.	Independent Claim 1 of the '213 Patent is anticipated by Jones [Ex. 1033].....	137
2.	Claims 2, 25, and 29 of the '213 Patent is anticipated by Jones [Ex. 1033].....	139
3.	Independent Claim 66 and Dependent Claims 71, 73, and 75-78 are Anticipated by Jones .....	140
4.	Claims 4, 62, 64, and 69 are anticipated by Jones .....	141
5.	Independent Claim 80 and Dependent Claim 81 Are Anticipated by Jones .....	144
<b>E.</b>	Claim 63 is anticipated by Jones, or obvious in view of Jones [Ex. 1033] and Riechmann [Ex. 1069] .....	145
<b>F.</b>	Claims 1, 2, 4, 25, 29, 62—64, 66-67, 69 and 71-73, 75-78, and 80-81 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	147
1.	Independent Claim 1 of the '213 Patent is obvious in view of Queen 1989 and the PDB database.....	147
2.	Independent Claim 1 of the '213 Patent is obvious in view of Queen 1990 and the PDB database.....	160

3.	Dependent Claims 2, 25 and 29 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database .....	163
4.	Dependent claim 4 of the '213 Patent is obvious in view of Queen 1990 and the PDB database.....	164
5.	Independent Claim 62 of the '213 Patent is obvious in view of Queen 1990 and the PDB database.....	164
6.	Independent Claim 63 of the '213 Patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	165
7.	Independent Claim 64 of the '213 Patent is obvious in view of Queen 1990 and the PDB database.....	166
8.	Independent Claim 66 of the '213 Patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	168
9.	Dependent Claims 67, 71-73 and 78 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database .....	170
10.	Dependent Claim 72 of the '213 patent is obvious in view of Queen 1989 or Queen 1990, and the PDB database.....	171
11.	Dependent Claim 75 of the '213 patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	172
12.	Dependent Claim 75 of the '213 patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database, and further in view of Tramontano.....	174
13.	Dependent Claims 76-77 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database, and optionally in view of Tramontano .....	175
14.	Dependent Claim 69 of the '213 Patent is obvious in view of Queen 1990 and the PDB database.....	183
15.	Independent Claim 80 of the '213 Patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	183
16.	Dependent Claim 81 of the '213 Patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	186
G.	Claims 4, 62, 64 and 69 of the '213 Patent are obvious in view of Queen 1989, the PDB database and in view of Kabat 1987 .....	186
1.	Independent Claim 62 of the '213 Patent is obvious in view of Queen 1989, the PDB database and in view of Kabat 1987...	186
2.	Dependent Claims 4 and 69 of the '213 Patent are obvious in view of Queen 1989 and the PDB database, and in view of Kabat 1987 .....	189

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.